AMEX, PLX - Protalix Biotherapeutics
We are a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins based on our proprietary
ProCellExtm protein expression system. Using our ProCellEx system, we are
developing a pipeline of proprietary recombinant therapeutic proteins based on
our plant cell-based expression technology that target large, established
pharmaceutical markets and that rely upon known biological mechanisms of action.
Our initial commercial focus has been on complex therapeutic proteins, including
proteins for the treatment of genetic disorders, such as Gaucher disease and
Fabry disease, and on female infertility disorders. We believe our ProCellEx
protein expression system will enable us to develop proprietary recombinant
proteins that are therapeutically equivalent or superior to existing recombinant
proteins currently marketed for the same indications. ...
Read SEC Filing on NASDAQ.com »